AbbVie and J&J look to broaden Imbruvica's use; Theravance and Mylan kick off COPD Phase III;

@FierceBiotech: ICYMI: FierceBiotech Radio on GSK's latest setback, Kyle Bass' 'truthful irrelevancy,' and Horizon's web presence. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: UPDATED: Melinta's CEO steps down amid a big Phase III push. Article | Follow @JohnCFierce

> Shire ($SHPG) is reportedly considering sweetening its offer for Baxalta ($BXLT) after a $30 billion, all-stock proposal received a lukewarm reception from shareholders. More

> Partners Theravance ($TBPH) and Mylan ($MYL) started Phase III development of revefenacin, a new COPD treatment. News

> AbbVie ($ABBV) and Johnson & Johnson ($JNJ) are working to expand the label for their cancer drug Imbruvica, filing for FDA approval in treatment-naive chronic lymphocytic leukemia. Item

Medical Device News

@FierceMedDev: ICYMI Friday: Startup Velico nabs another $15.5M from BARDA for dried plasma tech. Story | Follow @FierceMedDev

@EmilyWFierce: A little background on the FDA's regulation of drug marketing. More from The Atlantic | Follow @EmilyWFierce

> Qualcomm buys medical device connectivity player Capsule Tech. More

> Cantel to buy endoscope cleanliness startup for $80M. Article

Pharma News

@FiercePharma: ICYMI: Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explains. Article | Follow @FiercePharma

@EricPFierce: ICYMI: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. More | Follow @EricPFierce

@CarlyHFierce: ICYMI: Boehringer's Ofev, chasing a Roche rival, wins backing from NICE. Story | Follow @CarlyHFierce

> Shire casts about for creative ways to woo Baxalta shareholders. Story

> Advera Health Analytics: Merck statins linked to more muscle side effects than rest of class. Article

Animal Health News

> Phibro doubles earnings as demand for specialty animal products skyrockets. More

> Regulatory challenges top of mind at inaugural ACI animal health forum. Report

> FDA issues groundbreaking rules for manufacturing safe pet foods. Story

> McDonald's commits to cage-free eggs. Item

> USDA, poultry producers warn MN officials to expect bird flu resurgence. Article

Biotech IT News

> IBM inks deals to give Watson a role in R&D at Icon and Teva. News

> GSK picks Siemens as preferred supplier of automation tech. Report

> HudsonAlpha pairs HiSeq X Ten with Dragen processor to boost throughput. More

> Adaptimmune poaches GSK vet to lead biometrics team. Story

> AstraZeneca commits $18M to clinical trial bioinformatics collaboration. Article

Pharma Marketing News

> Surprise: J&J moves $1B U.S. media buying account back to Interpublic. Article

> Sanofi's combo med LixiLan ready to go to FDA in ongoing scramble for diabetes dominance. Report

> Diabetes rivalries get more complicated with new FDA warning on J&J's Invokana. Story

> AstraZeneca's lauded 'Take it From a Fish' campaign scores again at Clio Healthcare awards. More

> AZ's high-powered Crestor could gain from payer limits on PCSK9 meds. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.